Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Bratt

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
European Urology|July 24, 1998
Clinical course of early onset prostate cancer with special reference to family history as a prognostic factorO Bratt, U Kristoffersson, H Olsson, et al.
The Journal of Urology|May 7, 2002
Hereditary prostate cancer: clinical characteristics and survivalO Bratt, J-E Damber, M Emanuelsson, et al.
Scandinavian Journal of Urology and Nephrology|February 3, 2006
CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern SwedenM Wagenius, A Borg, L Johansson, et al.
Acta Anaesthesiologica Scandinavica|July 16, 2003
Acupuncture fails to reduce but increases anaesthetic gas required to prevent movement in response to surgical incisionN Kvorning, C Christiansson, A Beskow, et al.
Urology|February 1, 1996
Metaphase cytogenetics and DNA flow cytometry with analysis of S-phase fraction in prostate cancer: influence on prognosisO Bratt, H Anderson, E Bak-Jensen, et al.
Lakartidningen|May 2, 1998
[Research progress on hereditary prostatic cancer. Families at risk should be surveyed and screening should be offered]O Bratt, P A Abrahamsson, R Lundgren, et al.
British Journal of Cancer|November 26, 1999
CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer riskO Bratt, A Borg, U Kristoffersson, et al.
Cancer Genetics and Cytogenetics|July 17, 2001
Amplification of hypoxia-inducible factor 1alpha gene in prostate cancerO R Saramäki, K J Savinainen, N N Nupponen, et al.
British Journal of Cancer|September 17, 2009
Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancerO Bratt, M Häggman, G Ahlgren, et al.
World Journal of Urology|October 22, 2013
¹⁸F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancerH Kjölhede, G Ahlgren, H Almquist, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
European Urology|July 24, 1998
Clinical course of early onset prostate cancer with special reference to family history as a prognostic factorO Bratt, U Kristoffersson, H Olsson, et al.
The Journal of Urology|May 7, 2002
Hereditary prostate cancer: clinical characteristics and survivalO Bratt, J-E Damber, M Emanuelsson, et al.
Scandinavian Journal of Urology and Nephrology|February 3, 2006
CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern SwedenM Wagenius, A Borg, L Johansson, et al.
Acta Anaesthesiologica Scandinavica|July 16, 2003
Acupuncture fails to reduce but increases anaesthetic gas required to prevent movement in response to surgical incisionN Kvorning, C Christiansson, A Beskow, et al.
Urology|February 1, 1996
Metaphase cytogenetics and DNA flow cytometry with analysis of S-phase fraction in prostate cancer: influence on prognosisO Bratt, H Anderson, E Bak-Jensen, et al.
Lakartidningen|May 2, 1998
[Research progress on hereditary prostatic cancer. Families at risk should be surveyed and screening should be offered]O Bratt, P A Abrahamsson, R Lundgren, et al.
British Journal of Cancer|November 26, 1999
CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer riskO Bratt, A Borg, U Kristoffersson, et al.
Cancer Genetics and Cytogenetics|July 17, 2001
Amplification of hypoxia-inducible factor 1alpha gene in prostate cancerO R Saramäki, K J Savinainen, N N Nupponen, et al.
British Journal of Cancer|September 17, 2009
Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancerO Bratt, M Häggman, G Ahlgren, et al.
World Journal of Urology|October 22, 2013
¹⁸F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancerH Kjölhede, G Ahlgren, H Almquist, et al.
Pageof 3